Arbor Vita Corporation Presents New Data on Cancer Diagnostic at EUrogin
Published: Nov 14, 2008
NICE, FRANCE--(Marketwire - November 14, 2008) - Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, presented new data today on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer. Targeted for use throughout the developing world, this diagnostic test is being developed in partnership with PATH. The presentation, "Development of a Rapid Diagnostic Test for Cervical Pre-Cancer and Cancer," was given during the "Molecular Markers" session at Eurogin 2008, an international conference providing a comprehensive overview of current scientific advances in the field of cervical cancer control, including early detection.